If Channel Inhibition - Ivabradine for the Treatment of Heart Failure

Abstract

The novel first-in-class If channel antagonist, Ivabradine, is effective in improving clinical outcomes and functional capacity, in patients with HF, as well as demonstrating useful anti-anginal and protective anti-ischaemic effects. It can help improve heart rate control and can be usefully co-administered with beta blockers on HFrEF patients with residually elevated resting sinus rhythm heart rate. We review the clinical trial evidence for the benefits of Ivabradine in the treatment of heart failure.

Keywords

• heart failure
• ivabradine
• clinical trial